Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
2019; Massachusetts Medical Society; Volume: 381; Issue: 18 Linguagem: Inglês
10.1056/nejmoa1908681
ISSN1533-4406
AutoresKevin R. Flaherty, Athol U. Wells, Vincent Cottin, Anand Devaraj, Simon Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser, Carl Coeck, Emmanuelle Clerisme-Beaty, Bernd Rosenstock, Manuel Quaresma, Thomas Haeufel, Rainer-Georg Goeldner, Rozsa Schlenker‐Herceg, Kevin K. Brown,
Tópico(s)Sarcoidosis and Beryllium Toxicity Research
ResumoPreclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the efficacy of nintedanib has been shown in idiopathic pulmonary fibrosis, its efficacy across a broad range of fibrosing lung diseases is unknown.
Referência(s)